Show simple item record

dc.contributor.authorMcAuley, Daniel F.
dc.contributor.authorLaffey, John G.
dc.contributor.authorO'Kane, Cecilia M.
dc.contributor.authorPerkins, Gavin D.
dc.contributor.authorMullan, Brian
dc.contributor.authorTrinder, T. John
dc.contributor.authorJohnston, Paul
dc.contributor.authorHopkins, Philip A.
dc.contributor.authorJohnston, Andrew J.
dc.contributor.authorMcDowell, Cliona
dc.contributor.authorMcNally, Christine
dc.contributor.author,
dc.date.accessioned2018-09-20T16:16:31Z
dc.date.available2018-09-20T16:16:31Z
dc.date.issued2014-10-30
dc.identifier.citationMcAuley, Daniel F. Laffey, John G.; O'Kane, Cecilia M.; Perkins, Gavin D.; Mullan, Brian; Trinder, T. John; Johnston, Paul; Hopkins, Philip A.; Johnston, Andrew J.; McDowell, Cliona; McNally, Christine; , (2014). Simvastatin in the acute respiratory distress syndrome. New England Journal of Medicine 371 (18), 1695-1703
dc.identifier.issn0028-4793,1533-4406
dc.identifier.urihttp://hdl.handle.net/10379/12709
dc.description.abstractBACKGROUND Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS. METHODS In this multicenter, double-blind clinical trial, we randomly assigned (in a 1: 1 ratio) patients with an onset of ARDS within the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety. RESULTS The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between the study groups in the mean (+/- SD) number of ventilator-free days (12.6 +/- 9.9 with simvastatin and 11.5 +/- 10.4 with placebo, P = 0.21) or days free of nonpulmonary organ failure (19.4 +/- 11.1 and 17.8 +/- 11.7, respectively; P = 0.11) or in mortality at 28 days (22.0% and 26.8%, respectively; P = 0.23). There was no significant difference between the two groups in the incidence of serious adverse events related to the study drug. CONCLUSIONS Simvastatin therapy, although safe and associated with minimal adverse effects, did not improve clinical outcomes in patients with ARDS.
dc.publisherNew England Journal of Medicine (NEJM/MMS)
dc.relation.ispartofNew England Journal of Medicine
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectacute lung injury
dc.subjectrandomized controlled-trial
dc.subjectclinical-trial
dc.subjectreductase inhibition
dc.subjectsepsis
dc.subjectinflammation
dc.subjectmortality
dc.subjectstatins
dc.titleSimvastatin in the acute respiratory distress syndrome
dc.typeArticle
dc.identifier.doi10.1056/nejmoa1403285
dc.local.publishedsourcehttp://wrap.warwick.ac.uk/87722/1/WRAP-Simvastin-Acute-Syndrome-Perkins-2017.pdf
nui.item.downloads0


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland